Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEX dose-finding study in first-line advanced gastric cancer
2008-002697-35Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Mar 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin and capecitabine in gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoints: Dose-limiting toxicity and Recommended docetaxel dose. Started Mar 2009; status: completed.
02
Drugs
docetaxeloxaliplatincapecitabine
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2008-002697-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002697-35.